Prenatal genetic testing can estimate or diagnose certain chromosome and gene conditions during pregnancy. Screening tests—such as cell-free DNA, first-trimester screening, and the second-trimester quad screen—calculate the chance of selected conditions but cannot confirm them. Diagnostic tests—chorionic villus sampling and amniocentesis—collect placental or fetal cells and can provide a much more definitive answer for the conditions analyzed.
Every pregnant patient should have the opportunity to discuss both screening and diagnostic options, regardless of age or baseline risk. The right choice depends on what information is wanted, how early it is needed, the pregnancy’s ultrasound findings, family history, and how a result might affect care. A high-risk cell-free DNA result should usually be confirmed before an irreversible decision because false positives occur. A low-risk result reduces risk but does not guarantee an unaffected fetus. Test scope also matters: a screen for trisomy 21 does not evaluate every chromosome disorder, birth difference, or single-gene condition.
- Prenatal screening estimates risk; CVS and amniocentesis provide diagnostic information for the tests performed on the sample.
- Cell-free DNA can usually begin at about 10 weeks and is the most accurate screening method for trisomies 21, 18, and 13.
- A positive screening result should be followed by genetic counseling, detailed ultrasound, and an offer of diagnostic testing.
- CVS is generally performed earlier than amniocentesis, but placental mosaicism can sometimes complicate CVS results.
- A “no-call” cell-free DNA result is not reassuring and needs follow-up because low fetal fraction can be associated with test failure and increased aneuploidy risk.
- A normal genetic test cannot rule out all birth defects, developmental conditions, or pregnancy complications.
Table of Contents
- Screening and Diagnostic Testing
- Prenatal Screening Options
- CVS and Amniocentesis
- Choosing the Laboratory Analysis
- Understanding Results
- Special Situations and Limitations
- Planning Next Steps
Screening and Diagnostic Testing
The most important distinction in prenatal genetics is whether a test estimates risk or directly analyzes cells from the pregnancy for diagnosis.
A screening test is designed for broad use. It combines biological measurements with pregnancy information to identify pregnancies more or less likely to have selected conditions. The result may be “high risk,” “screen positive,” “low risk,” or a numerical probability. Screening can have excellent sensitivity and specificity while still producing false positives and false negatives.
A diagnostic test obtains chorionic villi from the placenta or cells in amniotic fluid. The laboratory can then perform chromosome analysis, chromosomal microarray, or testing for a specific gene condition. Diagnostic testing is highly accurate for the abnormalities the chosen assay can detect, but it does not guarantee that every fetal health condition has been ruled out.
| Feature | Screening | Diagnostic testing |
|---|---|---|
| Main purpose | Estimate chance of selected conditions | Determine whether a tested chromosome or gene finding is present |
| Examples | Cell-free DNA, first-trimester combined screening, quad screen | Chorionic villus sampling, amniocentesis |
| Pregnancy procedure | Maternal blood draw and/or ultrasound | Needle or catheter sampling under ultrasound guidance |
| Result type | Probability or risk category | Laboratory finding for the tested condition |
| Can confirm aneuploidy? | No | Yes, with appropriate chromosome testing |
Screening is optional, and diagnostic testing is also optional. Some people want as much information as possible early in pregnancy. Others prefer only information that can change prenatal care, delivery planning, or newborn treatment. Some would continue the pregnancy regardless of diagnosis but want time to prepare. Others prefer not to know. Informed choice includes the option to decline.
Age alone should not determine whether options are discussed. Although chromosome conditions become more common with maternal age, they can occur at any age. Current guidance supports offering screening and diagnostic choices to all pregnant patients.
The test choice should follow the question. A family with a known pathogenic CFTR variant pair needs targeted prenatal diagnosis for cystic fibrosis, not merely a chromosome screen. A fetus with several structural anomalies may need chromosomal microarray or broader sequencing rather than cell-free DNA alone. A person primarily seeking trisomy screening may reasonably choose cfDNA without invasive testing.
Prenatal testing also differs from carrier screening. Carrier screening usually tests the prospective parents to estimate the chance of an autosomal recessive or X-linked condition. When both parents carry variants for the same recessive disorder, fetal diagnostic testing can determine whether the fetus inherited the affected combination. The broader concepts of genetic screening apply, but pregnancy adds time-sensitive choices and placental biology.
Prenatal Screening Options
Prenatal screening can use maternal blood, ultrasound, or both. The exact menu varies by region, pregnancy type, and health system.
Cell-free DNA screening
Cell-free DNA screening, also called cfDNA screening or NIPT, analyzes short DNA fragments in maternal blood. Most of the fragments come from the pregnant person; the pregnancy-related fraction largely comes from the placenta. Because placental and fetal DNA are usually similar, the test can screen for fetal chromosome-number conditions.
CfDNA is generally available from about 10 weeks. It is the most sensitive and specific screening test for trisomy 21, trisomy 18, and trisomy 13. Many laboratories also offer sex chromosome aneuploidy screening. Some add microdeletions, rare autosomal trisomies, or genome-wide copy-number findings, but performance and clinical utility are less established for many expanded targets. A larger menu does not automatically mean a better screen.
The result depends strongly on prevalence. Positive predictive value—the chance that a positive result is truly affected—is higher when the condition is more likely before testing. A highly accurate screen can still have a modest positive predictive value for a very rare condition.
CfDNA is not “fetal whole-genome testing.” It typically evaluates selected chromosome signals. It can also reflect placental mosaicism, a maternal chromosome variant, maternal mosaicism, a vanished twin, organ transplant DNA, or rarely maternal disease. Those biological sources help explain why diagnostic confirmation is needed after a high-risk result.
First-trimester combined screening
First-trimester screening usually combines ultrasound measurement of nuchal translucency with maternal serum markers and age-related information. It is performed within a defined early gestational window. It screens for common trisomies and can provide information not captured by cfDNA alone, particularly through the ultrasound examination.
Nuchal translucency can be increased in chromosome conditions, heart defects, genetic syndromes, and some structurally normal fetuses. An enlarged measurement may justify diagnostic testing and detailed imaging even when cfDNA is low risk.
Second-trimester serum screening
The quad screen measures four substances in maternal blood, usually during the second trimester. It estimates risk for trisomy 21 and trisomy 18 and can help screen for open neural tube defects through alpha-fetoprotein. It is less accurate for common aneuploidies than cfDNA but remains useful when cfDNA is unavailable, declined, or begun too late for first-trimester options.
Ultrasound
Ultrasound is not a comprehensive genetic test, but it is central to prenatal assessment. A first-trimester scan confirms viability, number of fetuses, dating, and some major anomalies. A detailed anatomy scan, commonly around 18–22 weeks, examines fetal structures and placental features.
A normal ultrasound does not rule out aneuploidy or a single-gene condition. An abnormal ultrasound may increase concern even after low-risk screening and can guide the choice of diagnostic assay. Ultrasound and genetic testing answer overlapping but different questions.
Avoiding multiple independent screens
Using two unrelated screening methods for the same chromosome conditions can create conflicting results and a higher combined false-positive rate. A patient may still receive ultrasound and neural-tube-defect screening alongside cfDNA, but clinicians generally choose one primary aneuploidy screening strategy rather than stacking several risk calculations without a plan.
A screen can be declined in favor of diagnostic testing. Someone with a known familial chromosome rearrangement, a prior affected pregnancy, a high-risk ultrasound, or a strong preference for certainty may choose CVS or amniocentesis directly.
CVS and Amniocentesis
Chorionic villus sampling and amniocentesis are procedures, not laboratory tests by themselves. The procedure obtains a sample; the clinician and laboratory decide which analyses to run.
Chorionic villus sampling
CVS samples small projections of placental tissue. It is generally performed in the late first trimester, commonly around 10–13 weeks depending on local guidance and operator practice. The specialist may pass a thin catheter through the cervix or a needle through the abdomen under continuous ultrasound guidance.
Advantages include earlier diagnosis and earlier access to results. Limitations include the fact that the sample is placental. In confined placental mosaicism, some placental cells carry a chromosome abnormality that is absent from the fetus. A mosaic or discordant CVS result may therefore require amniocentesis for clarification.
CVS does not directly measure amniotic-fluid alpha-fetoprotein for open neural tube defects. Later serum screening and ultrasound remain relevant.
Amniocentesis
Amniocentesis is generally performed at or after 15 weeks. Under ultrasound guidance, a clinician inserts a thin needle through the abdomen into the amniotic sac and removes a small amount of fluid. The fluid contains fetal cells and biochemical markers.
Amniocentesis occurs later than CVS but samples cells shed by the fetus into amniotic fluid, which can simplify some mosaicism questions. It can also support testing for open neural tube defects. Early amniocentesis before the recommended gestational age is avoided because complication risk is higher.
Procedure-related risk
Both procedures can cause temporary cramping or spotting. Uncommon complications include fluid leakage, infection, bleeding, Rh sensitization, and pregnancy loss. Contemporary estimates depend on operator skill, center experience, gestational age, and the underlying risk of the pregnancy. Guidance commonly describes the additional miscarriage risk with a skilled operator as below 0.5%, and many studies estimate it lower. A local center should provide its own data rather than using one universal number.
Rh-negative patients may need anti-D immune globulin according to local protocol. Fever, heavy bleeding, persistent fluid leakage, severe pain, contractions, or feeling very unwell after a procedure requires prompt medical contact.
Choosing between the procedures
Factors include:
- gestational age;
- how early results are wanted;
- placental location and access;
- whether placental mosaicism is a concern;
- need for neural-tube-defect testing;
- prior screening and ultrasound results;
- operator expertise; and
- personal tolerance for procedure risk and waiting.
Neither procedure automatically performs every available genetic analysis. Before consent, ask exactly what the laboratory will test, what may be missed, how long each result takes, and whether parental samples are needed.
Choosing the Laboratory Analysis
Once CVS or amniotic fluid is collected, the laboratory analysis should match the clinical question. The same sample can often support more than one test, but more testing also increases the chance of uncertain or unexpected findings.
Rapid aneuploidy testing
Fluorescence in situ hybridization or quantitative fluorescent PCR can provide preliminary information about common chromosome-number conditions within a few days. It examines selected chromosomes and does not replace a full karyotype or microarray when broader information is needed.
Karyotype
A karyotype examines the number and large-scale structure of chromosomes. It can detect trisomies, monosomies, large rearrangements, and balanced translocations. Its resolution is lower than chromosomal microarray, so smaller deletions and duplications may be missed.
Karyotype is especially useful when a parent carries a balanced chromosome rearrangement or when the structure of an abnormality matters for recurrence counseling.
Chromosomal microarray
Microarray evaluates DNA copy number across the genome and detects deletions or duplications too small for a standard karyotype. It is often recommended when one or more major fetal structural anomalies are seen. It may also be offered with invasive testing in a structurally normal pregnancy.
Microarray can identify a variant of uncertain significance, susceptibility finding with incomplete penetrance, or an unexpected relationship result. It generally does not detect balanced rearrangements, most single-nucleotide variants, or every form of mosaicism.
Targeted single-gene testing
When the family has a known pathogenic variant, the laboratory can test specifically for it. Both parental variants may be assessed for an autosomal recessive condition. The test should use the original family report and confirm sample identity and maternal-cell contamination controls.
Targeted testing is more definitive for the known condition than a broad screen. A normal chromosome result does not rule out the familial gene disorder unless that gene was separately analyzed.
Prenatal exome or genome sequencing
Exome sequencing may be considered when ultrasound shows one or more significant anomalies, karyotype and microarray are nondiagnostic, and a single-gene disorder is suspected. Trio analysis of fetal and parental DNA improves interpretation. Genome sequencing is emerging but is not routine in all prenatal settings.
Broad sequencing can increase diagnostic yield, yet it also brings uncertain variants, incomplete knowledge of fetal presentation, incidental findings, and time pressure. It should be paired with specialized pre- and post-test counseling. The general limitations of whole-exome sequencing are amplified prenatally because many features cannot be assessed before birth.
Testing for infection, biochemical disease, or other causes
Not every abnormal ultrasound has a genetic cause. Depending on findings, amniotic fluid may be tested for congenital infection, enzyme activity, or other markers. Prenatal diagnosis is often multidisciplinary rather than a single DNA test.
Understanding Results
Prenatal results must be read in light of whether the test was screening or diagnostic, what sample was analyzed, and what conditions were included.
Low-risk or screen-negative
A low-risk screening result means the chance of the screened condition is lower after testing. It is not zero. Residual risk depends on test sensitivity, the condition, fetal fraction, gestational age, and prior probability. Routine ultrasound remains important, and diagnostic testing can still be chosen later.
A screen that is low risk for trisomy 21 says nothing definitive about most single-gene disorders, autism, intellectual disability, cerebral palsy, structural anomalies, or pregnancy complications.
High-risk or screen-positive
A high-risk result means the screen detected a pattern associated with a condition. The next steps should include genetic counseling, ultrasound review, and an offer of CVS or amniocentesis. The choice of procedure can depend on the suspected condition and gestational age.
The report may list positive predictive value. This is more useful than sensitivity alone for understanding an individual positive result. If the laboratory does not provide it, a clinician can estimate it using validated tools and the patient’s context.
Pregnancy decisions should not be based on cfDNA alone when diagnostic confirmation is available and desired. Placental mosaicism and maternal findings can create discordance.
No-call or test failure
A no-call result occurs when the laboratory cannot produce a reliable answer. Common reasons include low fetal fraction, early gestational age, higher maternal weight, sample problems, anticoagulation, placental biology, or assay limitations. Some aneuploidies are associated with low fetal fraction, so failure should not be treated as low risk.
Options may include detailed ultrasound, repeat cfDNA in selected circumstances, or diagnostic testing. Repeating can delay diagnosis and may fail again. The best choice depends on gestational age, ultrasound, reason for failure, and personal preference.
Positive diagnostic result
A diagnostic result may identify aneuploidy, a pathogenic copy-number change, or a disease-causing gene variant. The team should explain expected features, variability, limitations of prenatal prediction, pregnancy and delivery implications, newborn treatment, and reproductive recurrence risk.
A pathogenic result does not always predict severity. Some conditions have broad outcomes, and prenatal ultrasound may show only part of the phenotype. Families deserve balanced information, including condition-specific specialists and support resources rather than only worst-case descriptions.
Normal diagnostic result
A normal karyotype, microarray, or targeted test rules out the abnormalities that assay was designed to detect with high confidence. It does not rule out all genetic disease. The report’s limitations identify what remains untested.
Uncertain or mosaic result
A VUS should not be treated as a confirmed disorder. Parental testing, literature review, ultrasound correlation, and reanalysis may help. Mosaic results require careful attention to sample source and level. CVS mosaicism may be confined to the placenta; amniocentesis or additional studies may clarify fetal involvement.
Special Situations and Limitations
Twin and higher-order pregnancies require test-specific counseling. CfDNA performs well for common trisomies in many twin pregnancies, but fetal fraction, a vanished twin, egg-donor conception, and whether twins share a placenta can affect interpretation. A positive result may not show which fetus is affected.
A vanished twin can release placental DNA for weeks and cause a false-positive or confusing cfDNA result. Diagnostic testing may be preferable when accurate assignment is important.
Donor egg, gestational carrier, transplant history, maternal chromosome variants, and maternal cancer can also affect cfDNA. The laboratory needs relevant history before analysis.
Maternal-cell contamination can compromise CVS or amniotic-fluid results if maternal cells are mistaken for fetal cells. Clinical laboratories use identity and contamination checks, especially for targeted molecular testing.
Mosaicism can occur in the placenta, fetus, or pregnant person. The percentage detected in one sample does not always predict distribution across fetal tissues. The report may require confirmation with a different specimen.
Timing creates tradeoffs. Earlier testing provides more time for preparation and decisions, but early ultrasound may not reveal later-developing features. Later testing can integrate more anatomy information but leaves less time for confirmation and consultation. Laws governing pregnancy termination vary by location and can change; patients need current local information from qualified clinicians, not assumptions.
A normal prenatal result cannot guarantee health. Many birth differences have nongenetic causes, multifactorial causes, or genetic mechanisms outside current assays. Developmental and behavioral outcomes are especially difficult to predict from prenatal DNA alone.
Direct-to-consumer or nonstandard expanded screens may advertise detection of many microdeletions or single-gene disorders from maternal blood. Ask for condition-specific validation, false-positive rates, no-call rates, independent evidence, and professional guidance. “Noninvasive” describes sample collection, not certainty or absence of psychological harm.
Planning Next Steps
Before testing, decide what information would be useful and what action might follow. A concise pretest checklist includes:
- Which conditions does the test evaluate?
- Is it screening or diagnostic?
- When can it be performed, and when will results return?
- What are the chances of a false positive, false negative, no-call, or VUS?
- What confirmatory test would follow an abnormal result?
- What procedure risks apply at this center?
- Could the test reveal maternal or unexpected findings?
- How would results affect pregnancy care, delivery, or newborn care?
After a high-risk screen, arrange genetic counseling and maternal-fetal medicine review promptly. Bring the complete laboratory report. Do not rely on a portal label alone. Ultrasound may refine the question, but a normal scan does not convert a positive cfDNA result into a negative one.
After a diagnostic result, ask for the exact laboratory finding, classification, inheritance, expected range of outcomes, and whether parental testing is needed. Discuss all available options in a non-directive setting. These may include continuing the pregnancy with specialist planning, neonatal or palliative consultation, adoption planning, or pregnancy termination where legal and desired. The healthcare team should support the patient’s informed decision rather than assume a preferred outcome.
If continuing an affected pregnancy, prenatal diagnosis can guide fetal echocardiography, serial ultrasound, delivery location, timing, neonatal specialists, surgery, metabolic precautions, or comfort-focused care. It can also connect families with others who have lived experience.
After a normal result, continue routine obstetric care and recommended ultrasound. Revisit testing if new structural findings appear, because a test chosen earlier may not cover the newly suspected condition.
Seek urgent obstetric care for heavy bleeding, severe or persistent abdominal pain, fever, fluid leakage, contractions, fainting, or reduced fetal movement at a gestational age when movement is normally established. After CVS or amniocentesis, follow the procedural team’s specific instructions.
Prenatal genetic testing is most helpful when the difference between screening and diagnosis stays clear. The test should answer a defined question, use the right sample and method, and lead to timely, respectful counseling for every possible result.
References
- Current ACOG Guidance 2025 (Guideline)
- Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance 2025 (Guideline)
- Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) 2023 (Guideline)
- An overview of current prenatal genetic screening and diagnosis guidelines 2025 (Review)
- Amniocentesis and Chorionic Villus Sampling (Green-top Guideline No. 8) 2021 (Guideline)
- Comparative analysis of obstetric, perinatal, and children’s neurodevelopmental outcomes following chorionic villus sampling or amniocentesis: a population-based cohort study 2024
Disclaimer
This information is educational and does not replace prenatal care, genetic counseling, or advice from an obstetric or maternal-fetal medicine specialist. Screening results are not diagnoses, and diagnostic procedures and laboratory choices require individualized discussion. Seek urgent obstetric care for heavy bleeding, fluid leakage, fever, severe pain, contractions, fainting, or other concerning symptoms.
